News & Updates

Show Multimedia Only
OnabotulinumtoxinA as effective as, safer than pharmacotherapy for OAB

OnabotulinumtoxinA as effective as, safer than pharmacotherapy for OAB

02 Oct 2025 byStephen Padilla

Women with refractory overactive bladder (OAB) may improve their symptoms by using either intradetrusor onabotulinumtoxinA or combined pharmacotherapy with solifenacin and mirabegron, suggests a study.

02 Oct 2025
Long COVID symptoms may persist 3 years post-infection

Long COVID symptoms may persist 3 years post-infection

01 Oct 2025 byAudrey Abella

One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.

01 Oct 2025